nr-04: Bilingual Reader - Elecoglipron SOLSTICE Trial

Info

Module: paper-summary | Medicine | L2 | PASS

Source

Aroda et al., The Lancet (2026)

Output (Excerpt)

English	Chinese
Elecoglipron is an oral, small molecule GLP-1 receptor agonist currently in development for type 2 diabetes.	Elecoglipron 是一种口服小分子 GLP-1 受体激动剂，目前正在开发用于治疗 2 型糖尿病。
SOLSTICE evaluated the efficacy, safety, and tolerability of elecoglipron versus placebo.	SOLSTICE 评估了 elecoglipron 对比安慰剂的疗效、安全性和耐受性。
Elecoglipron reduced HbA1c in a dose-dependent manner, with the highest dose achieving a placebo-adjusted reduction of ~1.5 percentage points.	Elecoglipron 以剂量依赖方式降低 HbA1c，最高剂量实现安慰剂调整后降幅约 1.5 个百分点。